Development and Evaluation of Diclofenac Sodium Loaded-N-Trimethyl Chitosan Nanoparticles for Ophthalmic Use

AAPS PharmSciTech

Volumn 16, Issue 5, 2015, Pages 1013-1024

  Asasutjarit, Rathapon ^a   Theerachayanan, Thitaree ^b   Kewsuwan, Prartana ^c   Veeranodha, Sukitaya ^d   Fuongfuchat, Asira ^e   Ritthidej, Garnpimol C ^f  

^a THAMMASAT UNIVERSITY   (Thailand)

^b RANGSIT UNIVERSITY   (Thailand)

^c Thailand Institute of Nuclear Technology Public Organization   (Thailand)

^d NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^e NATIONAL METAL AND MATERIALS TECHNOLOGY CENTER   (Thailand)

^f CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

diclofenac sodium; N trimethyl chitosan nanoparticles; ophthalmic drug absorption; ophthalmic drug delivery; physicochemical properties

Indexed keywords

AGENTS ACTING ON THE EYE; BUFFER; CHITOSAN NANOPARTICLE; DICLOFENAC; N TRIMETHYL CHITOSAN NANOPARTICLE; PHOSPHATE; TRIPOLYPHOSPHATE; UNCLASSIFIED DRUG; CHITOSAN; DRUG CARRIER; EYE DROPS; N-TRIMETHYL CHITOSAN CHLORIDE; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYPHOSPHATE; TRIPHOSPHORIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; EYE IRRITATION; FEMALE; GELATION; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RABBIT; SYNTHESIS; ZETA POTENTIAL; ANIMAL; AQUEOUS HUMOR; BIOAVAILABILITY; CHEMICAL MODEL; CHEMISTRY; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; METABOLISM; NANOMEDICINE; PH; PROCEDURES; SOLUBILITY;

ADMINISTRATION, OPHTHALMIC; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; CHITOSAN; DICLOFENAC; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, CHEMICAL; NANOMEDICINE; NANOPARTICLES; OCULAR ABSORPTION; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; POLYPHOSPHATES; RABBITS; SOLUBILITY;

EID: 84944514703     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-015-0290-4     Document Type: Article

References (43)

1. Hao J, Wang X, Bi Y, Teng Y, Wang J, Li F, et al. Fabrication of a composite system combining solid lipid nanoparticles and thermosensitive hydrogel for challenging ophthalmic drug delivery. Colloids Surf B: Biointerf. 2014;114:111–20.
2. Badawi AA, El-Laithy HM, El Qidra RK, El Mofty H, El Dally M. Arch Pharm Res. 2008;31:1040–9.
3. Qi H, Gao X, Zhang L, Wei S, Bi S, Yang Z, et al. In vitro evaluation of enhancing effect of borneol on transcorneal permeation of compounds with different hydrophilicities and molecular sizes. Eur J Pharmacol. 2013;705:20–5.
4. Glisoni RJ, García-Fernández MJ, Pino M, Gutkind G, Moglioni AG, Alvarez-Lorenzo C, et al. β-Cyclodextrin hydrogels for the ocular release of antibacterial thiosemicarbazones. Carbohydr Polym. 2013;93:449–57.
5. Ameeduzzafar AJ, Bhatnagar A, Kumar N, Ali A. Chitosan nanoparticles amplify the ocular hypotensive effect of cateolol in rabbits. Int J Biol Macromol. 2014;65:479–91.
6. Mealy JE, Fedorchak MV, Little SR. In vitro characterization of a controlled-release ocular insert for delivery of brimonidine tartrate. Acta Biomater. 2014;10:87–93.
7. Araújo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine. 2009;5:394–401.
8. de la Fuente M, Raviña M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Del Rev. 2010;62:100–17.
9. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine. 2010;6:324–33.
10. Gan L, Wang J, Jiang M, Bartlett H, Ouyang D, Eperjesi F, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today. 2013;18:290–7.
11. Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm. 2009;379:131–8.
12. de Britto D, Frederico FR, Assis OBG. Optimization of N, N, N-trimethyl chitosan synthesis by factorial design. Polym Int. 2011;60:910–5.
13. Wang S, Zhang J, Jiang T, Zheng L, Wang Z, Zhang J, et al. Protective effect of coenzyme Q10 against oxidative damage in human lens epithelial cells by novel ocular drug carriers. Int J Pharm. 2011;403:219–29.
14. Zambito Y, Zaino C, Colo GD. Effect of N-trimethylchitosan on transcellular and paracellular transcorneal drug transport. Eur J Pharm Biopharm. 2006;64:16–25.
15. Zhang J, Wang S. Topical use of coenzyme Q10-loaded liposomes coated with trimethylchitosan: tolerance, precorneal retention and anti-cataract effect. Int J Pharm. 2009;372:66–75.
16. Ahuja M, Sharma SK, Majumdar DK. In vitro corneal permeation of diclofenac from oil drops. Yakugaku Zasshi. 2007;127:1739–45.
17. Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm. 2008;355:307–13.
18. Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine. 2009;5:90–5.
19. Polnok A, Borchard G, Verhoef JC, Sarisuta N, Junginger HE. Influence of methylation process on the degree of quaternization of N-trimethyl chitosan chloride. Eur J Pharm Biopharm. 2004;57:77–83.
20. Mourya VK, Inamdar NN. Trimethyl chitosan and its applications in drug delivery. J Mater Sci Mater Med. 2009;20:1057–79.
21. Chen F, Zhang Z, Huang Y. Evaluation and modification of N-trimethyl chitosan chloride nanoparticles as protein carriers. Int J Pharm. 2007;336:166–73.
22. Takahashi Y, Koike M, Honda H, Ito Y, Sakaguchi H, Suzuki H, et al. Development of the short time exposure (STE) test: an in vitro eye irritation test using SIRC cells. Toxicol in Vitro. 2008;22:760–70.
23. Bozdağ S, Gümüş K, Gümüş Ö, Ünlü N. Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis. Eur J Pharm Biopharm. 2008;70:260–9.
24. Wu C, Qi H, Chen W, Huang C, Su C, Li W, et al. Preparation and evaluation of a carbopol/HPMC-based in situ gelling ophthalmic system for puerarin. Yakgaku Zasshi. 2007;127183–91.
25. Riegel M, Ellis PP. High-performance liquid chromatographic assay for antiinflammatory agents diclofenac and flurbiprofen in ocular fluids. J Chromatogr B Biomed Appl. 1994;654:140–5.
26. Martins AF, Pereira AGB, Fajardo AR, Rubira AF, Muniz EC. Characterization of polyelectrolytes complexes based on N, N, N-trimethyl chitosan/heparin prepared at different pH conditions. Carbohydr Polym. 2011;86:1266–72.
27. de Britto D, Campana-Filho SP, Assis OBG. Mechanical properties of N, N, N- trimethylchitosan chloride films. Polímeros. 2005;15:142–5.
28. Rodrigues S, Costa AMR, Grenha A. Chitosan/Carrageenan nanoparticles: effect of cross-linking with tripolyphosphate and charge ratios. Carbohydr Polym. 2012;89:282–9.
29. Jintapattanakit A, Junyaprasert VB, Mao S, Sitterberg J, Bakowsky U, Kissel T. Peroral delivery of insulin using chitosan derivatives: a comparative study of polyelectrolyte nanocomplexes and nanoparticles. Int J Pharm. 2007;342:240–9.
30. De Campos AM, Sánchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm. 2001;224:159–68.
31. Fan W, Yan W, Xu Z, Ni H. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloid Surf B Biointerf. 2012;90:21–7.
32. Subbiah R, Ramalingam P, Ramasundaram S, Kim DY, Park K, Ramasamy MK, et al. N, N, N-Trimethyl chitosan nanoparticles for controlled intranasal delivery of HBV surface antigen. Carbohydr Polym. 2012;89:1289–97.
33. de Britto D, de Moura MR, Aouada FA, Mattoso LHC, Assis OBG. N, N, N-trimethyl chitosan nanoparticles as a vitamin carrier system. Food Hydrocolloid. 2012;27:487–93.
34. Antoniou J, Liu F, Majeed H, Qi J, Yokoyama W, Zhong F. Physicochemical and morphological properties of size-controlled chitosan–tripolyphosphate nanoparticles. Colloids Surf A Physicochem Eng Asp. 2015;465:137–46.
35. Llinàs A, Burley JC, Box KJ, Glen RC, Goodman JM. Diclofenac solubility: independent determination of the intrinsic solubility of three crystal forms. J Med Chem. 2007;50:979–83.
36. Kumar M, Pandey RS, Patra KC, Jain SK, Soni ML, Dangi JS, et al. Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery. Int J Biol Macromol. 2013;61:189–95.
37. Freitas C, Müller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int J Pharm. 1998;168:221–9.
38. Hansson A, Di Francesco T, Falson F, Rousselle P, Jordan O, Borchard G. Preparation and evaluation of nanoparticles for directed tissue engineering. Int J Pharm. 2012;439:73–80.
39. Rampino A, Borgogna M, Blasi P, Bellich B, Cesàro A. Chitosan nanoparticles: preparation, size evolution and stability. Int J Pharm. 2013;455:219–28.
40. Bharathi A, Srinivas NK, Reddy GR, Veeranjaneyulu M, Sirisha A, Kamala P. Formulation and in vitro evaluation of diclofenac sodium sustained release matrix tablets using melt granulation technique. Int J Res Pharm Biomed Sci. 2011;2:788–808.
41. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67:217–23.
42. Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix- controlled drug delivery systems. J Control Release. 2001;73:121–36.
43. Nishihata T, Keigami M, Kamada A, Fujimoto T, Kamide S, Tatsumi N. Clinical investigation of sodium diclofenac sustained-release suppositories. Int J Pharm. 1988;42:251–6.